AC Immune (ACIU) Cash from Financing Activities (2015 - 2024)
AC Immune (ACIU) posted quarterly Cash from Financing Activities of -$224879.8 for Q4 2024, down 100.49% year-over-year from $46.3 million in Q1 2024, and down 12.62% quarter-over-quarter from -$199677.9 in Q3 2024.
AC Immune (ACIU) Cash from Financing Activities (2015 - 2024) Analysis & Trends
AC Immune (ACIU) has reported Cash from Financing Activities for 10 consecutive years, with -$224879.8 the latest figure, recorded in Q4 2024.
- In Q4 2024, Cash from Financing Activities fell 100.49% year-over-year to -$224879.8; the TTM figure through Dec 2024 stood at $46.3 million (changed 0.26% YoY), while the FY2025 annual figure was -$1.2 million, up 3.77% from the prior year.
- Cash from Financing Activities slipped to -$224879.8 in Q4 2024 per ACIU's latest filing, from -$199677.9 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $46.3 million in Q4 2023 and bottomed at -$991852.5 in Q1 2022.
- Historically, Cash from Financing Activities has averaged $5.5 million across 5 years, with a median of -$126646.0 in 2020.
- Annual changes were most pronounced in 2020 — Cash from Financing Activities slumped 6195.03% — and 2023, when it soared 29609.2%.
- AC Immune's Cash from Financing Activities stood at -$508831.6 in 2020, then surged by 6224.03% to $31.2 million in 2021, then tumbled by 100.5% to -$156741.3 in 2022, then jumped by 29609.2% to $46.3 million in 2023, then sank by 100.49% to -$224879.8 in 2024.
- Business Quant data shows ACIU's Cash from Financing Activities at -$224879.8 in Q4 2024, -$199677.9 in Q3 2024, and $46.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -224,879.80 |
| Dec 31, 2024 | -224,879.80 |
| Sep 30, 2024 | -199,677.85 |
| Sep 30, 2024 | -199,677.85 |
| Dec 31, 2023 | 46.25 Mn |
| Dec 31, 2023 | 46.25 Mn |
| Sep 30, 2023 | 507,204.35 |
| Sep 30, 2023 | 507,204.35 |
| Dec 31, 2022 | -156,741.31 |
| Dec 31, 2022 | -156,741.31 |
| Sep 30, 2022 | -147,034.84 |
| Sep 30, 2022 | -147,034.84 |
| Jun 30, 2022 | -142,246.14 |
| Jun 30, 2022 | -142,246.14 |
| Mar 31, 2022 | -991,852.47 |
| Mar 31, 2022 | -991,852.47 |
| Dec 31, 2021 | 31.16 Mn |
| Dec 31, 2021 | 31.16 Mn |
| Sep 30, 2021 | 4.71 Mn |
| Sep 30, 2021 | 4.71 Mn |